Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer : a review of the existing clinical trials and results of the expanded access programme in the UK
Papazisis, K. T., Habeshaw, T., Miles, D. W., Herceptin EAP Study Group, & O'Byrne, Kenneth J. (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer : a review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58(6), pp. 581-586.
Trastuzumab is a humanised monoclonal antibody against the extracellular domain of HER2 (human epidermal growth factor receptor-2) that is overexpressed in about 25% of human breast cancers. It has shown clinical benefit in HER2-positive breast cancer cases when used alone or in combination with chemotherapy. Trastuzumab increases the response rate to chemotherapy and prolongs survival when used in combination with taxanes. In this article, we review the clinical trials where trastuzumab has been administered together with docetaxel, and we present the results of the trastuzumab expanded access programme (EAP) in the UK. Combination of trastuzumab with docetaxel results in similar response rates and time-to-progression with the trastuzumab/paclitaxel combinations. The toxicity of the combination and the risk of heart failure are low. The clinical data for the docetaxel/trastuzumab combination indicate a favourable profile from both the efficacy and the safety point of view and confirm the feasibility and safety of trastuzumab administration both as monotherapy and in combination with docetaxel. © 2004 Blackwell Publishing Ltd.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
|Item Type:||Journal Article|
|Keywords:||anthracycline derivative, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, epidermal growth factor receptor 2, epipodophyllotoxin, navelbine, paclitaxel, trastuzumab, Vinca alkaloid, advanced cancer, breast cancer, cancer combination chemotherapy, cancer survival, clinical trial, congestive heart failure, disease course, drug efficacy, drug mechanism, drug potentiation, drug safety, drug withdrawal, feasibility study, health care access, heart atrium fibrillation, heart failure, heart left ventricle ejection fraction, human, in vitro study, monotherapy, neutropenia, priority journal, review, risk assessment, supraventricular tachycardia, time, treatment outcome, United Kingdom, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Clinical Trials, Female, Humans, Multicenter Studies, Randomized Controlled Trials, Receptor, erbB-2, Survival Analysis, Taxoids|
|Divisions:||Current > Schools > School of Biomedical Sciences
Current > QUT Faculties and Divisions > Faculty of Health
Current > Institutes > Institute of Health and Biomedical Innovation
|Copyright Owner:||Copyright 2004 Wiley-Blackwell Publishing Ltd.|
|Deposited On:||12 Dec 2013 01:47|
|Last Modified:||08 Jan 2014 00:33|
Repository Staff Only: item control page